Predominant expression of truncated EpCAM is associated with a more aggressive phenotype and predicts poor overall survival in colorectal cancer
出版年份 2016 全文链接
标题
Predominant expression of truncated EpCAM is associated with a more aggressive phenotype and predicts poor overall survival in colorectal cancer
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF CANCER
Volume 139, Issue 3, Pages 657-663
出版商
Wiley
发表日期
2016-03-21
DOI
10.1002/ijc.30099
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro
- (2015) Andreas Seeber et al. BMC CANCER
- Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: Tumor budding as oncotarget
- (2015) Oncotarget
- Nuclear Ep-ICD accumulation predicts aggressive clinical course in early stage breast cancer patients
- (2014) Gunjan Srivastava et al. BMC CANCER
- Dynamic EpCAM expression on circulating and disseminating tumor cells: causes and consequences
- (2014) Olivier Gires et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Expression of EpCAMMFand EpCAMMTvariants in human carcinomas
- (2014) Dominic Fong et al. JOURNAL OF CLINICAL PATHOLOGY
- Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980
- (2013) C. Bosetti et al. ANNALS OF ONCOLOGY
- EpCAM proteolysis: new fragments with distinct functions?
- (2013) Ulrike Schnell et al. BIOSCIENCE REPORTS
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer
- (2013) Dominic Fong et al. HISTOPATHOLOGY
- Context-dependent adaption of EpCAM expression in early systemic esophageal cancer
- (2013) C Driemel et al. ONCOGENE
- Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer
- (2012) M. Schmidt et al. ANNALS OF ONCOLOGY
- Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines
- (2012) Agnieszka Martowicz et al. BMC CANCER
- EpCAM regulates cell cycle progression via control of cyclin D1 expression
- (2012) A Chaves-Pérez et al. ONCOGENE
- EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells
- (2011) M. Cioffi et al. CLINICAL CANCER RESEARCH
- Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group
- (2011) K. Baumann et al. GYNECOLOGIC ONCOLOGY
- Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites
- (2011) Marion G. Ott et al. INTERNATIONAL JOURNAL OF CANCER
- Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110
- (2011) Silke Petsch et al. mAbs
- EpCAM nuclear localization identifies aggressive Thyroid Cancer and is a marker for poor prognosis
- (2010) Ranju Ralhan et al. BMC CANCER
- Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM and ALDH1 in colorectal cancer
- (2010) A Lugli et al. BRITISH JOURNAL OF CANCER
- Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy
- (2010) Diane Seimetz et al. CANCER TREATMENT REVIEWS
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
- (2010) Markus M. Heiss et al. INTERNATIONAL JOURNAL OF CANCER
- Phase II Study of the Human Anti-Epithelial Cell Adhesion Molecule Antibody Adecatumumab in Prostate Cancer Patients with Increasing Serum Levels of Prostate-Specific Antigen after Radical Prostatectomy
- (2010) Norbert Marschner et al. UROLOGIA INTERNATIONALIS
- An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer
- (2009) M. Schmidt et al. ANNALS OF ONCOLOGY
- EpCAM: Another Surface-to-Nucleus Missile
- (2009) Graham Carpenter et al. CANCER CELL
- The basics of epithelial-mesenchymal transition
- (2009) Raghu Kalluri et al. JOURNAL OF CLINICAL INVESTIGATION
- Adjuvant Therapy With the Monoclonal Antibody Edrecolomab Plus Fluorouracil-Based Therapy Does Not Improve Overall Survival of Patients With Stage III Colon Cancer
- (2009) Anthony L.A. Fields et al. JOURNAL OF CLINICAL ONCOLOGY
- Nuclear signalling by tumour-associated antigen EpCAM
- (2009) Dorothea Maetzel et al. NATURE CELL BIOLOGY
- Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status
- (2008) Alessandro Lugli et al. MODERN PATHOLOGY
- Innovations in Chemotherapy for Metastatic Colorectal Cancer: An Update of Recent Clinical Trials
- (2008) B. H. O'Neil et al. ONCOLOGIST
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started